“I can tell you that reducing the work force by 11 percent, removing $4 billion of ongoing costs from the system and coming up with a new business model to me seems pretty competitive.”
“We are engaged in an ongoing effort to enhance efficiencies throughout the company and improve the way we discover, develop, manufacture and market our medicines and vaccines.”